In work that has moved from the lab to the clinic and back, and is now poised to enter the clinic yet again, researchers have figured out how to manufacture and administer what they believe is the first highly effective malaria vaccine – one that can provide protection lasting at least six to 24 months to 80 percent of those vaccinated. Read More
Figuring out how to get chemotherapy directly into tumor cells while sparing healthy cells has long been one focus of cancer drug development. The trick is developing a targeted drug delivery vehicle that's actually capable of penetrating cells. Read More
Sagene Pharmaceuticals Inc., of Oldsmar, Fla., completed a pre-investigational new drug meeting with the FDA regarding erectile dysfunction drug SPI-1972, which combines the FDA-approved MAO-B inhibitor selegiline with a PDE-5 inhibitor such as Viagra (sildenafil, Pfizer Inc.) or Cialis (tadalafil, Eli Lilly and Co.). Read More
Probiodrug AG, of Halle, Germany, published data providing key insights into the onset and development of Alzheimer's disease (AD) in the Journal of Neuroscience. The research described the generation and characterization of a novel animal model that solely expresses N-truncated human amyloid-β (Aβ), which in turn is modified by the so-called QC enzyme (glutaminyl cyclase) to pyroglutamate residue Aβ. Read More
WASHINGTON – Patent reform became a reality Thursday evening when the Senate voted 89 to 9 to send the House version of the America Invents Act to the president for his signature. Read More
Elusys Therapeutics Inc. received a contract from the U.S. Biomedical Advanced Research & Development Authority (BARDA) for a second indication for its inhalational anthrax antitoxin Anthim (ETI-204). The five-year contract, totaling up to $68.9 million, is designed to develop an intramuscular (IM) formulation of Anthim for pre- and post-exposure prophylactic use. Read More
